USPTO serial 88428843
BAM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 29, 2020
- Examiner
- ALAO, OREOLUWA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with BAM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael A. Geller
Michael A. Geller DLA PIPER LLP (US)P.O. BOX 64807CHICAGO, IL 60664-0807UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Strategic business consulting, information and data collection, namely, compiling and analyzing data and information for business purposes, and business data analytics, namely, analyzing business data to understand and evaluate business performance, all of the aforementioned in the pharmaceutical, biotechnology and life sciences fields; market analysis and research services; personnel recruitment and placement; recruitment advertising services, namely, advertising clinical trials for the purpose of recruiting patients, and placing patients for participation in clinical trials for testing of pharmaceuticals and devices; consulting in sales techniques and sales programs; sales volume tracking for others, all in the pharmaceutical, biotechnology and life sciences fields; business consulting in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, pharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting pharmaceutical and biotechnology companies with preparing and filing applications for new drugs with governmental regulatory bodies; promoting the exchange of health information within the pharmaceutical, biotechnology and life sciences communities to promote patient adherence within the field of pharmaceutical, biotechnology and life sciences clinical trials; extended clinical research services for others, namely, computerized data management of clinical trials | ACTIVE | Jan 7, 2019 |
| 041 | Education services, namely, providing non-downloadable webinars, providing live workshops, providing seminars through on-line non-downloadable videos, providing on-line non-downloadable electronic publications in the nature of articles and white papers, and providing non-downloadable podcasts, all the foregoing in the field of pharmaceutical sales; training services in the field of pharmaceutical sales; providing on-line non-downloadable electronic newsletters and bulletins in the pharmaceutical, biotechnology and life sciences fields; educational services, namely, providing courses offered through on-line non-downloadable videos, non-downloadable webinars, live workshops, providing online non-downloadable electronic publications in the nature of articles and white papers, and providing non-downloadable podcasts, all the foregoing in the field of clinical trials | ACTIVE | Jan 7, 2019 |
| 042 | Medical and scientific data analysis research services for others, namely, conducting and analyzing clinical trials in the pharmaceutical, biotechnology and life sciences fields; pharmaceutical drug development services, namely, developing clinical trial methodologies; consulting services in the area of pharmaceutical product clinical testing; extended clinical research services for others for medical purposes, namely, biostatistical analysis for scientific research purposes, preclinical research in the field of pharmaceuticals, biotechnology, and medical sciences, development evaluation, namely, clinical feasibility assessment of protocols and patient recruitment strategies, repairing flawed clinical trials and dossiers, namely, medical and scientific research in the nature of conducting clinical trials for others, and strategic clinical research portfolio management, namely, consulting services for others in the project management of clinical research; extended clinical research services for others in the field of pharmaceuticals, biotechnology, and life sciences, namely, biostatistical analysis for scientific research purposes; providing life science and scientific research information to physicians and other health care professionals, patients, and medical, pharmaceutical and biotechnology companies; providing regulatory compliant technical writing services in the field of medical research and clinical studies; consulting services in the field of contract clinical research and contract product development | ACTIVE | Jan 7, 2019 |
| 044 | Providing medical information to physicians, other health care professionals and medical patients; providing health information regarding the medications and health care products of others through e-mail alerts and push notifications, namely, providing information concerning product discontinuations; providing health information concerning new formulations of medications and health care products of others through e-mail alerts and push notifications, namely, providing information in the field of pharmaceutical products development; providing health information concerning bottle changes of medications and health care products of others through e-mail alerts and push notifications, namely, providing information in the field of bottle product design, and seasonal information in the nature of reports on pharmaceutical products development | ACTIVE | Jan 7, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Syneos Health, LLC
- Other trademarks owned by Syneos Health, LLC
- Other trademarks owned by Syneos Health, LLC
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BAM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 4, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Mar 15, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Sep 29, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 23, 2020 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| May 14, 2020 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Apr 14, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 14, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 25, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 3, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 3, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 3, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 3, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 8, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 7, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 7, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 7, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 31, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 30, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 17, 2019 | NWAP | NEW APPLICATION ENTERED | — |